603 Baseline circulating tumor cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) Prognostic Score and improve patient selection for phase 1 clinical trials

Article2011

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono

Preprint2023

Supplementary Figure 1 from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono

Preprint2023

Supplementary Figure 1 from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono

Preprint2023

Data from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono

Preprint2023

Data from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono

Discussion(0)

Related publications

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Supplementary Figure 1 from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Supplementary Figure 1 from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Data from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Data from Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials